Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ling-Wen Ding is active.

Publication


Featured researches published by Ling-Wen Ding.


Nature Genetics | 2014

Genomic and molecular characterization of esophageal squamous cell carcinoma

De-Chen Lin; Jia-Jie Hao; Yasunobu Nagata; Liang Xu; Li Shang; Xuan Meng; Yusuke Sato; Yusuke Okuno; Ana Maria Varela; Ling-Wen Ding; Manoj Garg; Li-Zhen Liu; Henry Yang; Dong Yin; Zhi-Zhou Shi; Yan-Yi Jiang; Wen-Yue Gu; Ting Gong; Yu Zhang; Xin Xu; Ori Kalid; Sharon Shacham; Seishi Ogawa; Ming-Rong Wang; H. Phillip Koeffler

Esophageal squamous cell carcinoma (ESCC) is prevalent worldwide and particularly common in certain regions of Asia. Here we report the whole-exome or targeted deep sequencing of 139 paired ESCC cases, and analysis of somatic copy number variations (SCNV) of over 180 ESCCs. We identified previously uncharacterized mutated genes such as FAT1, FAT2, ZNF750 and KMT2D, in addition to those already known (TP53, PIK3CA and NOTCH1). Further SCNV evaluation, immunohistochemistry and biological analysis suggested their functional relevance in ESCC. Notably, RTK-MAPK-PI3K pathways, cell cycle and epigenetic regulation are frequently dysregulated by multiple molecular mechanisms in this cancer. Our approaches also uncovered many druggable candidates, and XPO1 was further explored as a therapeutic target because it showed both gene mutation and protein overexpression. Our integrated study unmasks a number of novel genetic lesions in ESCC and provides an important molecular foundation for understanding esophageal tumors and developing therapeutic targets.


Nature Genetics | 2014

The genomic landscape of nasopharyngeal carcinoma

De-Chen Lin; Xuan Meng; Masaharu Hazawa; Yasunobu Nagata; Ana Maria Varela; Liang Xu; Yusuke Sato; Li-Zhen Liu; Ling-Wen Ding; Arjun Sharma; Boon Cher Goh; Soo-Chin Lee; Bengt Fredrik Petersson; Feng Gang Yu; Paul A. MacAry; Min Zin Oo; Chan Soh Ha; Henry Yang; Seishi Ogawa; Kwok Seng Loh; H. Phillip Koeffler

Nasopharyngeal carcinoma (NPC) has extremely skewed ethnic and geographic distributions, is poorly understood at the genetic level and is in need of effective therapeutic approaches. Here we determined the mutational landscape of 128 cases with NPC using whole-exome and targeted deep sequencing, as well as SNP array analysis. These approaches revealed a distinct mutational signature and nine significantly mutated genes, many of which have not been implicated previously in NPC. Notably, integrated analysis showed enrichment of genetic lesions affecting several important cellular processes and pathways, including chromatin modification, ERBB-PI3K signaling and autophagy machinery. Further functional studies suggested the biological relevance of these lesions to the NPC malignant phenotype. In addition, we uncovered a number of new druggable candidates because of their genomic alterations. Together our study provides a molecular basis for a comprehensive understanding of, and exploring new therapies for, NPC.


Analytical Biochemistry | 2008

Using silica particles to isolate total RNA from plant tissues recalcitrant to extraction in guanidine thiocyanate.

Ling-Wen Ding; Qiao-Yang Sun; Zhaoyu Wang; Yong-Bin Sun; Zeng-Fu Xu

The most commonly used protocol of the RNA isolation, the guanidine thiocyanate method, was unsuitable for recalcitrant plant tissues containing a large amount of storage proteins and secondary metabolites. We demonstrated that RNA could bind to the silica particles, which have been used successfully in DNA isolation from various sources, under a high concentration of NaCl in the presence of ethanol and sodium acetate. Based on this observation, an efficient, inexpensive, and highly reproducible technique, the acid phenol-silica method, was developed to isolate high-quality RNAs from various plant tissues recalcitrant to extraction in guanidine thiocyanate.


Journal of Experimental & Clinical Cancer Research | 2013

SOX7 is down-regulated in lung cancer

Takahide Hayano; Manoj Garg; Dong Yin; Makoto Sudo; Norihiko Kawamata; Shuo Shi; Wenwen Chien; Ling-Wen Ding; Geraldine Leong; Seiichi Mori; Dong Xie; Patrick Tan; H. Phillip Koeffler

BackgroundSOX7 is a transcription factor belonging to the SOX family. Its role in lung cancer is unknown.MethodsIn this study, whole genomic copy number analysis was performed on a series of non-small cell lung cancer (NSCLC) cell lines and samples from individuals with epidermal growth factor receptor (EGFR) mutations using a SNP-Chip platform. SOX7 was measured in NSCLC samples and cell lines, and forced expressed in one of these lines.ResultsA notable surprise was that the numerous copy number (CN) changes observed in samples of Asian, non-smoking EGFR mutant NSCLC were nearly the same as those CN alterations seen in a large collection of NSCLC from The Cancer Genome Atlas which is presumably composed of predominantly Caucasians who often smoked. However, four regions had CN changes fairly unique to the Asian EGFR mutant group. We also examined CN changes in NSCLC lines. The SOX7 gene was homozygously deleted in one (HCC2935) of 10 NSCLC cell lines and heterozygously deleted in two other NSCLC lines. Expression of SOX7 was significantly downregulated in NSCLC cell lines (8/10, 80%) and a large collection of NSCLC samples compared to matched normal lung (57/62, 92%, p= 0.0006). Forced-expression of SOX7 in NSCLC cell lines markedly reduced their cell growth and enhanced their apoptosis.ConclusionThese data suggest that SOX7 is a novel tumor suppressor gene silenced in the majority of NSCLC samples.


Journal of Biotechnology | 2011

Improved expression and purification of recombinant human serum albumin from transgenic tobacco suspension culture

Qiao-Yang Sun; Ling-Wen Ding; George P. Lomonossoff; Yong-Bing Sun; Ming Luo; Chaoqiong Li; Liwen Jiang; Zeng-Fu Xu

Most human serum albumin (HSA) for medical applications is derived from human plasma due to the lack of suitable heterologous expression systems for recombinant HSA (rHSA). To determine whether plant cell cultures could provide an alternative source, we employed the hyper-translatable cowpea mosaic virus protein expression system (CPMV-HT) to stably express rHSA in tobacco Bright Yellow-2 (BY-2) cells. rHSA was stably produced with yield up to 11.88μg/ml in the culture medium, accounting for 0.7% of total soluble protein, in a 25-ml flask. Cultivation of transgenic cells in modified Murashige and Skoog medium with a pH of 8.0 improved the yield of rHSA two-fold, which may be the result of reduced proteolytic activity in the modified medium. A simple purification scheme was developed to purify the rHSA from culture medium, resulting in a recovery of 48.41% of the secreted rHSA. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and N-terminal sequence analysis of the purified rHSA revealed that plant cell-derived rHSA is identical to that of the plasma-derived HSA. Our results show that the CPMV-HT system, which was originally developed as a transient expression system for use in whole plants, can also be used for high-level expression of rHSA, a protein highly susceptible to proteolysis, in transgenic tobacco cells.


Blood | 2012

Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3

De-Chen Lin; Tong Yin; Maya Koren-Michowitz; Ling-Wen Ding; Saskia Gueller; Sigal Gery; Takayuki Tabayashi; Ulla Bergholz; Julhash U. Kazi; Lars Rönnstrand; Carol Stocking; H. Phillip Koeffler

Fms-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase with important roles in hematopoietic progenitor cell survival and proliferation. It is mutated in approximately one-third of AML patients, mostly by internal tandem duplications (ITDs). Adaptor protein Lnk is a negative regulator of hematopoietic cytokine signaling. In the present study, we show that Lnk interacts physically with both wild-type FLT3 (FLT3-WT) and FLT3-ITD through the SH2 domains. We have identified the tyrosine residues 572, 591, and 919 of FLT3 as phosphorylation sites involved in direct binding to Lnk. Lnk itself was tyrosine phosphorylated by both FLT3 ligand (FL)-activated FLT3-WT and constitutively activated FLT3-ITD. Both shRNA-mediated depletion and forced overexpression of Lnk demonstrated that activation signals emanating from both forms of FLT3 are under negative regulation by Lnk. Moreover, Lnk inhibited 32D cell proliferation driven by different FLT3 variants. Analysis of primary BM cells from Lnk-knockout mice showed that Lnk suppresses the expansion of FL-stimulated hematopoietic progenitors, including lymphoid-primed multipotent progenitors. The results of the present study show that through direct binding to FLT3, Lnk suppresses FLT3-WT/ITD-dependent signaling pathways involved in the proliferation of hematopoietic cells. Therefore, modulation of Lnk expression levels may provide a unique therapeutic approach for FLT3-ITD-associated hematopoietic disease.


The Journal of Clinical Endocrinology and Metabolism | 2014

Laminin-5γ-2 (LAMC2) Is Highly Expressed in Anaplastic Thyroid Carcinoma and Is Associated With Tumor Progression, Migration, and Invasion by Modulating Signaling of EGFR

Manoj Garg; Deepika Kanojia; Ryoko Okamoto; Saket Jain; Vikas Madan; Wenwen Chien; Abhishek Sampath; Ling-Wen Ding; Meng Xuan; Jonathan W. Said; Ngan Doan; Li-Zhen Liu; Henry Yang; Sigal Gery; Glenn D. Braunstein; H. Phillip Koeffler

CONTEXT Anaplastic thyroid carcinoma (ATC) is an aggressive malignancy having no effective treatment. Laminin subunit-γ-2 (LAMC2) is an epithelial basement membrane protein involved in cell migration and tumor invasion and might represent an ideal target for the development of novel therapeutic approaches for ATC. OBJECTIVE The objective of the investigation was to study the role of LAMC2 in ATC tumorigenesis. DESIGN LAMC2 expression was evaluated by RT-PCR, Western blotting, and immunohistochemistry in tumor specimens, adjacent noncancerous tissues, and cell lines. The short hairpin RNA (shRNA) approach was used to investigate the effect of LAMC2 knockdown on the tumorigenesis of ATC. RESULTS LAMC2 was highly expressed in ATC samples and cell lines compared with normal thyroid tissues. Silencing LAMC2 by shRNA in ATC cells moderately inhibited cell growth in liquid culture and dramatically decreased growth in soft agar and in xenografts growing in immunodeficient mice. Silencing LAMC2 caused cell cycle arrest and significantly suppressed the migration, invasion, and wound healing of ATC cells. Rescue experiments by overexpressing LAMC2 in LAMC2 knockdown cells reversed the inhibitory effects as shown by increased cell proliferation and colony formation. Microarray data demonstrated that LAMC2 shRNA significantly altered the expression of genes associated with migration, invasion, proliferation, and survival. Immunoprecipitation studies showed that LAMC2 bound to epidermal growth factor receptor (EGFR) in the ATC cells. Silencing LAMC2 partially blocked epidermal growth factor-mediated activation of EGFR and its downstream pathway. Interestingly, cetuximab (an EGFR blocking antibody) or EGFR small interfering RNA additively enhanced the antiproliferative activity of the LAMC2 knockdown ATC cells compared with the control cells. CONCLUSIONS To our knowledge, this is the first report investigating the effect of LAMC2 on cell growth, cell cycle, migration, invasion, and EGFR signaling in ATC cells, suggesting that LAMC2 may be a potential therapeutic target for the treatment of ATC.


Cancer Research | 2015

Genomic and Functional Analysis of the E3 Ligase PARK2 in Glioma.

De-Chen Lin; Liang Xu; Ye Chen; Haiyan Yan; Masaharu Hazawa; Ngan Doan; Jonathan W. Said; Ling-Wen Ding; Li-Zhen Liu; Henry Yang; Shizhu Yu; Michael Kahn; Dong Yin; H. Phillip Koeffler

PARK2 (PARKIN) is an E3 ubiquitin ligase whose dysfunction has been associated with the progression of Parkinsonism and human malignancies, and its role in cancer remains to be explored. In this study, we report that PARK2 is frequently deleted and underexpressed in human glioma, and low PARK2 expression is associated with poor survival. Restoration of PARK2 significantly inhibited glioma cell growth both in vitro and in vivo, whereas depletion of PARK2 promoted cell proliferation. PARK2 attenuated both Wnt- and EGF-stimulated pathways through downregulating the intracellular level of β-catenin and EGFR. Notably, PARK2 physically interacted with both β-catenin and EGFR. We further found that PARK2 promoted the ubiquitination of these two proteins in an E3 ligase activity-dependent manner. Finally, inspired by these newly identified tumor-suppressive functions of PARK2, we tested and proved that combination of small-molecule inhibitors targeting both Wnt-β-catenin and EGFR-AKT pathways synergistically impaired glioma cell viability. Together, our findings uncover novel cancer-associated functions of PARK2 and provide a potential therapeutic approach to treat glioma.


The Journal of Pathology | 2015

SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway.

Qiao-Yang Sun; Ling-Wen Ding; Jinfen Xiao; Wenwen Chien; Susan M. L. Lim; Norimichi Hattori; Lee Goodglick; David Chia; Mah; Mohammad Alavi; Kim; Ngan Doan; Jonathan W. Said; Xin-Yi Loh; Liang Xu; Li-Zhen Liu; Henry Yang; Takahide Hayano; Shuo Shi; Dong Xie; De-Chen Lin; Koeffler Hp

We investigated the oncogenic role of SETDB1, focusing on non‐small cell lung cancer (NSCLC), which has high expression of this protein. A total of 387 lung cancer cases were examined by immunohistochemistry; 72% of NSCLC samples were positive for SETDB1 staining, compared to 46% samples of normal bronchial epithelium (106 cases) (p <0.0001). The percentage of positive cells and the intensity of staining increased significantly with increased grade of disease. Forced expression of SETDB1 in NSCLC cell lines enhanced their clonogenic growth in vitro and markedly increased tumour size in a murine xenograft model, while silencing (shRNA) SETDB1 in NSCLC cells slowed their proliferation. SETDB1 positively stimulated activity of the WNT–β‐catenin pathway and diminished P53 expression, resulting in enhanced NSCLC growth in vitro and in vivo. Our finding suggests that therapeutic targeting of SETDB1 may benefit patients whose tumours express high levels of SETDB1. Copyright


Analytical Biochemistry | 2009

Culture of Escherichia coli in SOC medium improves the cloning efficiency of toxic protein genes

Qiao-Yang Sun; Ling-Wen Ding; Liang-Liang He; Yong-Bin Sun; Jun-Li Shao; Ming Luo; Zeng-Fu Xu

In this paper, we report a useful protocol for cloning toxic protein genes. Use of the SOC medium, which is a glucose-containing rich medium, significantly improved the transformation efficiency of a recombinant plasmid containing a toxic plant subtilase SaSBT1 cDNA. Both glucose and rich nutrients present in the SOC medium prevented the unintended activation of the lac promoter carried on the cloning vector, and led to significantly improved transformation efficiency of recombinant plasmids containing toxic protein genes and an increased rate of transformant growth.

Collaboration


Dive into the Ling-Wen Ding's collaboration.

Top Co-Authors

Avatar

H. Phillip Koeffler

National University of Singapore

View shared research outputs
Top Co-Authors

Avatar

Henry Yang

National University of Singapore

View shared research outputs
Top Co-Authors

Avatar

De-Chen Lin

Cedars-Sinai Medical Center

View shared research outputs
Top Co-Authors

Avatar

Qiao-Yang Sun

National University of Singapore

View shared research outputs
Top Co-Authors

Avatar

Anand Mayakonda

National University of Singapore

View shared research outputs
Top Co-Authors

Avatar

Liang Xu

National University of Singapore

View shared research outputs
Top Co-Authors

Avatar

Wenwen Chien

National University of Singapore

View shared research outputs
Top Co-Authors

Avatar

Li-Zhen Liu

National University of Singapore

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ngan Doan

University of California

View shared research outputs
Researchain Logo
Decentralizing Knowledge